Lung factor

International treatment recommendation and medicine for idiopathic pulmonary fibrosis

The International ATS / ERS guideline for idiopathic pulmonary disease treatment was updated in 2015 and the first medicines for the prevention of disease progression, pirfenidone and nintedanibi, were approved in the 2010s. These advances require examination of the effectiveness of the treatment in our patients and harmonizing treatment recommendations.

Facing a difficult clinical problem using applied medicine

The research group’s motto is: Keep it simple. Our staff are competent and focused on doing what they have been educated for. The group is small in size and the operations are based on a solid cooperation network and good planning. We consider it important that science benefits society, not just investigators. We strive to estimate the best possible utilization of inventions in our work. Follow us also on Facebook and Twitter.

Copyright: Pinja Sutinen

 

Now at Lung factor / News

Ethical board approval for the FikSu -study

The ethical board at the Helsinki University Central Hospital has […]

BMC Pulm Med classifies our work as highly accessed

Our systematic review on IPF epidemiology has been ranked as […]

Finnish update on IPF in Duodecim

In the latest issue of Duodecim,  Finnish researchers publish an […]

Follow us on Facebook

Are you interested in our research? Please like us on […]

Archive »